Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Ligand Pharmaceuticals Incorporated (LGND)

90.39   -2.14 (-2.31%) 01-17 16:00
Open: 93.15 Pre. Close: 92.53
High: 93.19 Low: 89.62
Volume: 315,022 Market Cap: 1588M
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 93.243 - 93.719 93.719 - 94.085
Low: 88.529 - 89.021 89.021 - 89.399
Close: 89.613 - 90.436 90.436 - 91.068

Technical analysis

as of: 2020-01-17 4:37:49 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 119.33     One year: 129.01
Support: Support1: 88.77    Support2: 73.86
Resistance: Resistance1: 102.17    Resistance2: 110.45
Pivot: 97.50
Moving Average: MA(5): 91.02     MA(20): 99.93
MA(100): 102.94     MA(250): 109.91
MACD: MACD(12,26): -4.32     Signal(9): -3.32
Stochastic oscillator: %K(14,3): 13.21     %D(3): 12.16
RSI: RSI(14): 27.84
52-week: High: 130.50  Low: 84.45  Change(%): -19.9
Average Vol(K): 3-Month: 32443  10-Days: 33855

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
LGND has closed above bottom band by 19.1%. Bollinger Bands are 74.2% wider than normal. The large width of the bands suggest high volatility as compared to LGND's normal range. The bands have been in this wide range for 5 bars. This is a sign that the current trend might continue.

Headline News

Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. 2019 Fourth Quarter and Full Year Earnings Conference Call What: Ligand conference call to discuss financial results and provide general business updates Date: Thursday, Febr

Famed short-seller Andrew Left's hedge fund saw 43% returns in its 1st year
Citron Capital, the new hedge fund led by famed short-seller Andrew Left, gained 43% net of fees in 2019, Reuters reported Monday, citing a letter to investors. The fund includes both long and short positions. In 2019, the average exposure was 75.8% long and 80.3% short, Reuters reported, citing Left's letter to investors. Left also told investors that he's sticking to his bet against Peloton. In December, he gave the company a $5 price target , betting it will fall as much as 83% in a year. Read more on Business Insider. Citron Capital, the new hedge fund led by Andrew Left, had a solid first year. Left, the famed market-moving short-seller and leader of Citron Research, told investors on Monday that the hedge fund had a net return of 43% in 2019, its first year open, Reuters reported . The fund contains both long positions on companies Left sees poised to gain, and short positions against companies he thinks will fall. In 2019, the average exposure was 75.8% long and 80.3% short, Reuters reported, citing Left's letter to investors.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 17.56
Shares Float (M) 15.75
% Held by Insiders 4.03
% Held by Institutions 131.89
Shares Short (K) 7650
Shares Short P. Month (K)

Stock Financials

EPS 28.290
Book Value (p.s.) 48.430
PEG Ratio -8.60
Profit Margin 388.69
Operating Margin 24.60
Return on Assets (ttm) 1.3
Return on Equity (ttm) 76.7
Qtrly Rev. Growth -45.7
Gross Profit (p.s.) 12.372
Sales Per Share
EBITDA (p.s.) 3.565
Qtrly Earnings Growth
Operating Cash Flow (M) 10.57
Levered Free Cash Flow (M) 916.64

Stock Valuations

P/E 3.20
P/E Growth Ratio -0.02
P/BV 1.87
P/S 11.80
P/CF 150.17

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 2010-07-02
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.